Clinical Trial Update: A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD) [Phase 1]

View source ↗

Summary

Phase 1 study evaluating ARC-AAT in healthy volunteers and patients with Alpha-1 Antitrypsin Deficiency (AATD) was terminated; results were posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alpha-1 Antitrypsin Deficiency

Drugs mentioned

• ARC-AAT

Snippet

Sponsor: Arrowhead Pharmaceuticals | Conditions: Alpha-1 Antitrypsin Deficiency | Phase 1 | Status: TERMINATED | Results posted: 2018-08-03